Graft Versus Host Disease (GvHD) Treatment Market: Introduction
Graft versus host disease (GvHD) occurs following a donor stem cell transplant. GvHD is a frequent complication of bone marrow or stem cell transplantation using tissue from another person. Before transplantation, cells from possible donors are screened to understand how well donors’ cells match with that of recipients. Stem cell transplantation is utilized to treat various diseases related to the blood. The procedure involves replacing diseased or damaged cells with healthy cells from a donor.
Read Report Overview – https://www.transparencymarketresearch.com/graft-versus-host-disease-treatment-market.html
A donor’s stem cells contain white blood cells (T cells) that help fight infections. Graft versus host disease occurs when these T cells attack the patient’s own tissues, as the donated cells recognize the patient’s body cells as foreign tissue. GvHD affects various parts of the patient’s body. It most commonly affects the digestive system, liver, and skin. It is tough to predict who might develop graft versus host disease after a bone marrow or stem cell transplant. Chances of GvHD are reduced or symptoms are milder if the donor’s cells match closely with that of the recipient’s.
Key Drivers, Restraints, and Opportunities of Global Graft Versus Host Disease (GvHD) Treatment Market
Graft versus host disease is a major cause of morbidity and mortality following stem cell transplants. Research findings suggest that even after treatments with intensive immunosuppressive therapy, 50% to 70% of patients transplanted from unrelated donors and 30% to 50% of patients transplanted from fully matched sibling donors develop some level of graft versus host disease. Presently, the global graft versus host disease treatment market is expanding, due to a rise in the prevalence and incidence of cancer patients. These patients are usually under chemotherapy.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=59799
The global graft versus host disease treatment market is also driven by bone marrow transplants surgeries performed globally for specific types of cancers. Rise in allogeneic type of stem cell transplants is expected to boost the graft versus host disease treatment market. However, costs related to authorization and clinical trials of treatment therapies for GvHD are expected to restrain the global graft versus host disease (GvHD) treatment market.
North America to Capture Major Share of Global Graft Versus Host Disease (GvHD) Treatment Market
Based on region, the global graft versus host disease (GvHD) treatment market can be categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. In terms of region, the graft versus host disease (GvHD) treatment market in North America and Asia Pacific is estimated to expand at a rapid rate due to a large incidence and prevalence rate of the global graft versus host disease.
Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=59799
For instance, a research study suggests that around 30% to 50% of hematopoietic stem cell transplant (HSCT) recipients develop acute GVHD. That translates to 5500 patients/year who are likely to develop acute GVHD. Eventually, around 50% of patients with acute graft versus host disease have manifestations of chronic graft versus host disease.
The global graft versus host disease (GvHD) treatment market in Europe is also estimated to expand due to a rise in the geriatric population with cancer disease, improvements in medical research, and increase in clinical trials. The graft versus host disease (GvHD) treatment market in several regions is specifically driven by the adoption of advanced technologies in cancer treatment, increase in awareness about diseases, and rise in the number of chemotherapy treatments.
Pre Book Graft Versus Host Disease Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=59799<ype=S
Key Players Operating in Global Graft Versus Host Disease (GvHD) Treatment Market
The global graft versus host disease (GvHD) treatment market is highly fragmented, with the presence of various key players. Major Players operating in the global graft versus host disease (GvHD) treatment market are:
- Novartis AG
- Bristol-Myers Squibb
- Pfizer
- Hoffmann-La Roche
- AbbVie
- Astellas Pharma
- Merck & Co.
- Takeda Pharmaceutical
- Abbott
- Eli Lilly
- Merck & Co., Inc.
- Sanofi
- Neovii Pharmaceuticals AG
- Soligenix
- Mesoblast Ltd
- Johnson & Johnson Services, Inc.
- ElsaLys Biotech SA
- Kiadis Pharma,
- Genzyme Corporation
More Trending Reports by Transparency Market Research –
Hemophilia Treatment Drugs Market: https://www.biospace.com/article/fda-approvals-of-newer-drugs-bodes-well-for-hemophilia-treatment-drugs-market/
Hemostasis and Tissue Sealing Agents Market: https://www.biospace.com/article/hemostasis-and-tissue-sealing-agents-market-topical-hemostat-segment-to-dominate-market/
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
